Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma-Reference-Cited by-同舟云学术

Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma

Published:2019-10-29 Issue:21 Volume:3 Page:3214-3227
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Lin Yu-Hsiu T.¹^ORCID,Way Gregory P.²^ORCID,Barwick Benjamin G.³^ORCID,Mariano Margarette C.¹,Marcoulis Makeba¹,Ferguson Ian D.¹^ORCID,Driessen Christoph⁴,Boise Lawrence H.³,Greene Casey S.²⁵^ORCID,Wiita Arun P.¹^ORCID

Affiliation:

1. Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA;

2. Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA;

3. Department of Hematology and Medical Oncology and Winship Cancer Institute, Emory University, Atlanta, GA;

4. Experimental Oncology and Hematology, Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland; and

5. Childhood Cancer Data Laboratory, Alex’s Lemonade Stand Foundation, Philadelphia, PA

Abstract

Key Points NRAS and KRAS mutations lead to different downstream transcriptional signatures and patient prognoses under current myeloma therapies. RAS genotype alone does not strongly predict degree of active MAPK signaling, suggesting alternate precision medicine approaches are needed.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/21/3214/1506242/advancesadv2019000303.pdf

Reference51 articles.

1. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma;Bolli;Nat Commun,2014

2. Initial genome sequencing and analysis of multiple myeloma;Chapman;Nature,2011

3. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma;Laganà;Leukemia,2018

4. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy;Lohr;Cancer Cell,2014

5. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma;Walker;Blood,2018

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma;Blood Neoplasia;2024-09

2. TP53 function over forms in multiple myeloma;Blood;2024-03-28

3. Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma;Nature Communications;2022-09-17

4. The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma;Translational Oncology;2022-08

5. Widespread redundancy in -omics profiles of cancer mutation states;Genome Biology;2022-06-27